Huizenga Theodore Alan sold $17K of RARE

Huizenga Theodore Alan (SVP, Chief Accounting Officer) sold 1,283 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $13.57 on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Huizenga Theodore Alan
Published Sep 15, 2026, 10:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 11:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RARE
Bearish
medium confidence
Mentioned
$RARE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAREBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but it adds to the flow of insider activity data.

02

Market read

Primary source filing; adds a small data point for traders monitoring insider activity.

03

What to watch

The 10b5-1 plan indicates pre‑arranged execution, reducing speculation on motive.

Relevance 2/10Novelty 4/10Timing: same day

Background

Form 4 filing discloses insider transactions required by SEC, providing transparency on insider holdings.

Company-level read

Ticker impact

$RAREBearishMedium confidence
Context

Insider SVP sold 1,283 shares for $17.4K via a 10b5-1 plan, reducing holdings to 67,863 shares.

Expected impact

Potential modest dip of 0.5‑1% in near term.

Evidence & confidence

Sale size is small relative to float, but insider selling can be viewed negatively by traders.

Market effects

Limited impact on biotech sector; similar insider sales are common.

No regional effect.

Minimal global relevance.

Counterpoint

Sale may be routine portfolio rebalancing, not a signal of trouble.

Key entities

  • Ultragenyx Pharmaceutical Inc.

    Biotech firm focused on rare disease therapies.

  • Huizenga Theodore Alan

    SVP, Chief Accounting Officer of Ultragenyx.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.